title: Innovative drug vehicle for local treatment of inflammatory skin diseases: Ex vivo and in vivo screening of five topical formulations containing poly(lactic acid) (PLA) nanoparticles.
abstract: One of the main goals in the galenic development of innovative topical treatment options for inflammatory skin diseases such as psoriasis and atopic dermatitis is to selectively deliver the drug at the inflammation site. Recent studies have highlighted the beneficial use of polymeric nanoparticles for anti-inflammatory therapy and topical anti-inflammatory drug delivery due to their ability to form a drug reservoir retaining the drug locally at the site of action. Our approach consisted in designing innovative topical semi-solid formulations of poly(lactic acid) (PLA) nanoparticles as anti-inflammatory drug vehicles for local treatment of inflammatory skin diseases. In the course of this work, five topical formulations containing fluorescent PLA nanoparticles were initially developed, and then screened depending on their physico-chemical properties, toxicity and delivery efficacy. The penetration and permeation of a fluorophore vectorized by PLA nanoparticles into healthy and inflammatory skin were assessed using an alternative device to classical Franz cells: VitroPharma. All these investigations led to the selection of two satisfactory formulations out of five initial candidates.
authors.affiliation: UMR 5305: Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique, CNRS / Université Claude Bernard Lyon 1, Institut de Biologie et Chimie des Protéines, 7 passage du Vercors, 69367 Lyon cedex 07, France. Electronic address: asboisgard@ibcp.fr.
authors.forename: A-S
authors.initials: AS
authors.lastname: Boisgard
authors.affiliation: UMR 5305: Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique, CNRS / Université Claude Bernard Lyon 1, Institut de Biologie et Chimie des Protéines, 7 passage du Vercors, 69367 Lyon cedex 07, France.
authors.forename: M
authors.initials: M
authors.lastname: Lamrayah
authors.affiliation: UMR 5305: Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique, CNRS / Université Claude Bernard Lyon 1, Institut de Biologie et Chimie des Protéines, 7 passage du Vercors, 69367 Lyon cedex 07, France.
authors.forename: M
authors.initials: M
authors.lastname: Dzikowski
authors.affiliation: UMR 5305: Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique, CNRS / Université Claude Bernard Lyon 1, Plateforme FRIPHARM, Faculté de Pharmacie, 8 avenue Rockefeller, 69373 Lyon cedex 03, France; Unité de préparation et contrôle des médicaments, Service Pharmaceutique, Plateforme FRIPHARM, Groupement Hospitalier Edouard Herriot, Hospices Civils de Lyon, 5 place d'Arsonval, 69437 Lyon cedex 03, France.
authors.forename: D
authors.initials: D
authors.lastname: Salmon
authors.affiliation: UMR 5305: Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique, CNRS / Université Claude Bernard Lyon 1, Plateforme FRIPHARM, Faculté de Pharmacie, 8 avenue Rockefeller, 69373 Lyon cedex 03, France.
authors.forename: P
authors.initials: P
authors.lastname: Kirilov
authors.affiliation: Adjuvatis, 7 passage du Vercors, 69007 Lyon, France.
authors.forename: C
authors.initials: C
authors.lastname: Primard
authors.affiliation: UMR 5305: Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique, CNRS / Université Claude Bernard Lyon 1, Plateforme FRIPHARM, Faculté de Pharmacie, 8 avenue Rockefeller, 69373 Lyon cedex 03, France; Unité de préparation et contrôle des médicaments, Service Pharmaceutique, Plateforme FRIPHARM, Groupement Hospitalier Edouard Herriot, Hospices Civils de Lyon, 5 place d'Arsonval, 69437 Lyon cedex 03, France.
authors.forename: F
authors.initials: F
authors.lastname: Pirot
authors.affiliation: UMR 5305: Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique, CNRS / Université Claude Bernard Lyon 1, Institut de Biologie et Chimie des Protéines, 7 passage du Vercors, 69367 Lyon cedex 07, France.
authors.forename: B
authors.initials: B
authors.lastname: Fromy
authors.affiliation: UMR 5305: Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique, CNRS / Université Claude Bernard Lyon 1, Institut de Biologie et Chimie des Protéines, 7 passage du Vercors, 69367 Lyon cedex 07, France.
authors.forename: B
authors.initials: B
authors.lastname: Verrier
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000737:chemistry*; D002626:Chemistry, Pharmaceutical / Q000379:methods; D016503:Drug Delivery Systems / Q000379:methods; D007249:Inflammation / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D053758:Nanoparticles / Q000008:administration & dosage / Q000737:chemistry*; D011091:Polyesters / Q000008:administration & dosage / Q000737:chemistry*; D011108:Polymers / Q000008:administration & dosage / Q000737:chemistry*; D012867:Skin / Q000187:drug effects; D012869:Skin Absorption / Q000187:drug effects; D012871:Skin Diseases / Q000188:drug therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D011091:Polyesters; D011108:Polymers; C033616:poly(lactide)
keywords: Galenic development; Imiquimod-induced psoriasis; PLA nanoparticles; Psoriasis; Skin inflammatory disease; Topical treatment; VitroPharma